Search

Your search keyword '"Ozcakar B"' showing total 1 results
Start Over Author "Ozcakar B" Journal lung cancer amsterdam netherlands

Refine your results

1 results on '"Ozcakar B"'

1. HER2/neu intragenic kinase domain mutations may be major determinant of response to trastuzumab or specific kinase inhibitors in non-small cell lung cancer patients.

Author

Altundag O, Altundag K, Ozcakar B, and Silay YS

Subjects
Antibodies, Monoclonal, Humanized, Gene Amplification, Gene Expression Regulation, Neoplastic, Humans, Lung Neoplasms drug therapy, Lung Neoplasms genetics, Protein Kinase Inhibitors therapeutic use, Receptor, ErbB-2 metabolism, Trastuzumab, Antibodies, Monoclonal therapeutic use, Antineoplastic Agents therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung genetics, Drug Resistance, Neoplasm, Mutation genetics, Receptor, ErbB-2 genetics
Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results